Infectious Diseases

PRA’s record of accomplishment in program management and drug development in infectious diseases (ID) is clear to see. Our global experience includes services leading to the approval of 5 important products.

PRA has supported 170+ phase I-IV clinical STUDIES involving more than 3,400+ sites and 56,500+ patients in infectious diseases since 2010.

Experience and Expertise

Over 60% of PRA’s key project management and clinical operations employees are experienced in ID clinical research.

During the last five years, PRA has conducted studies across a wide-range of indications within vaccines, antibacterials, antivirals, antifungals, pneumonia and antiparasitics.

 

Key areas of ID Expertise

Therapeutic_Expertise_Infectious_Diseases_Key_Areas

Medical Informatics

PRA’s analytical Medical Informatics (MI) tool supplements our therapeutic expertise and practical experience with data derived from:

  • Laboratory, pharmacy, EMR, diagnostic and other databases
  • The MI group provides data related to natural disease histories, study protocol optimization and contextual informatics for site selection or enrichment of site-specific populations

Feasibility Studies

PRA’s Feasibility group gathers real-time ID survey data to identify suitable regions as well as appropriate clinics and patient populations. PRA’s advantages include:

  • Familiarity with ID investigators worldwide and the types of patients they treat, disease states and other key factors facilitating optimal site and patient selection
  • Ability to combine existing available data (including investigator metrics, study performance and Medical Informatics) with direct investigator feedback to minimize study start-up time
  • PRA utilizes US claims data to determine investigator locations as well as associated patient counts